Brokerages Expect Alimera Sciences Inc (NASDAQ:ALIM) to Announce -$0.03 Earnings Per Share
Equities research analysts expect Alimera Sciences Inc (NASDAQ:ALIM) to announce earnings per share (EPS) of ($0.03) for the current quarter, Zacks reports. Two analysts have made estimates for Alimera Sciences’ earnings, with the lowest EPS estimate coming in at ($0.03) and the highest estimate coming in at ($0.02). The business is scheduled to announce its next earnings results on Tuesday, February 4th.
On average, analysts expect that Alimera Sciences will report full-year earnings of ($0.18) per share for the current fiscal year, with EPS estimates ranging from ($0.18) to ($0.17). For the next year, analysts anticipate that the business will post earnings of ($0.07) per share, with EPS estimates ranging from ($0.07) to ($0.06). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Alimera Sciences.
Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). The business had revenue of $12.85 million during the quarter, compared to analysts’ expectations of $12.75 million.
ALIM stock traded down $0.03 on Friday, reaching $0.24. The company’s stock had a trading volume of 950,600 shares, compared to its average volume of 227,699. Alimera Sciences has a 12-month low of $0.23 and a 12-month high of $1.21. The business has a fifty day simple moving average of $0.40 and a two-hundred day simple moving average of $0.67.
A hedge fund recently raised its stake in Alimera Sciences stock. Renaissance Technologies LLC boosted its position in Alimera Sciences Inc (NASDAQ:ALIM) by 13.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,128,404 shares of the biopharmaceutical company’s stock after purchasing an additional 130,414 shares during the period. Renaissance Technologies LLC owned about 1.59% of Alimera Sciences worth $1,004,000 as of its most recent SEC filing. 50.32% of the stock is currently owned by institutional investors.
About Alimera Sciences
Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.
Featured Story: Mutual Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.